COVID-19 in persons with multiple sclerosis treated with ocrelizumab - a pharmacovigilance case series.

Authors
Category Primary study
JournalMultiple sclerosis and related disorders
Year 2020
This article has no abstract
Epistemonikos ID: cd860435660e7f4cd99bacc31eaea8a7afc663d7
First added on: May 21, 2020